Ancient Drug Solves Nighttime Pee Problem

A close-up view of a variety of colorful pills and tablets stacked together

A 1940s gout pill may soon help kidney patients sleep through the night without a bathroom marathon.

Story Snapshot

Old gout drug probenecid is being tested to tame the worst side effect of a major kidney drug.
Mayo Clinic researchers found a second “water-saving” kidney pathway that does not rely on vasopressin.
Early data suggest about a 30% drop in urine volume and fewer nighttime trips to the bathroom for some patients.^[16]
For now, the promise is real but limited to symptoms, not proven kidney survival or cyst-shrinking benefits.^[8]^[13]

A gout drug from World War II walks back on stage

Probenecid first showed up in the 1940s to help soldiers stretch their penicillin supply and to lower uric acid in gout.^[2]^[10] Doctors learned that it blocks certain kidney transporters and pushes uric acid out of the blood and into the urine.^[2] For decades it sat in a quiet corner of the pharmacy, overshadowed by newer gout drugs.^[9] Now kidney doctors are pulling it off the shelf for a very different reason: to help patients who cannot stay out of the bathroom.

Autosomal dominant polycystic kidney disease, or PKD, fills kidneys with fluid cysts and often leads to kidney failure. The one proven disease-slowing pill, tolvaptan, works by blocking the hormone vasopressin, which normally helps the kidneys save water. That blockage means patients pass huge volumes of very dilute urine and feel thirsty all day. Many need to drink and pee every hour, and wake up many times at night, which wears down work, family life, and simple sanity.

Mayo’s new “urate signal” pathway changes the script

Mayo Clinic researchers recently described a second way the kidney can concentrate urine that does not depend on vasopressin at all.^[16] Their lab work showed that urate, the same molecule tied to gout, can slip into certain kidney cells and act as a signal inside them.^[16] That signal helps move the water channel called aquaporin-2 to the cell surface. Once there, aquaporin-2 lets the kidney pull water back into the body and make the urine more concentrated, even when vasopressin is blocked.

Probenecid, long known as a urate-handling drug, became their tool to control that pathway.^[2]^[16] In animal and cell experiments, probenecid changed how urate moved and how those water channels behaved.^[16] In a mouse model of autosomal dominant PKD, blocking a related channel called pannexin-1 with probenecid slowed cyst growth and improved kidney filtering function, hinting at deeper disease effects.^[13] That animal work does not prove human benefit, but it gave a strong push to try the drug in real patients.^[13]

The small human trial that got everyone’s attention

Mayo then ran a phase 2 add-on trial in people with hereditary PKD already on tolvaptan.^[8]^[16] The public trial listing is blunt about its goal: test whether probenecid can safely slow the frequent urination caused by tolvaptan, not whether it prevents kidney failure.^[8]^[12] Early reporting from Mayo and press outlets says that when probenecid was added, average urine volume fell by about 30 percent.^[16] Patients who had been waking several times each night dropped to about once per night and reported better quality of life.^[16]

For a patient who lives chained to a water bottle and a bathroom, that is not a small gain. Better sleep and fewer daytime interruptions can make it easier to hold a job and take care of a family. Helping patients actually stay on a proven kidney-saving drug like tolvaptan may be the biggest payoff. If probenecid makes tolvaptan more tolerable, fewer people will quit it, which could quietly protect more kidneys over many years. That is a practical, patient-first benefit.

Why this is not ready for prime time yet

The catch is size and depth. Mayo’s reports describe “preclinical studies and a small clinical trial,” but the public record so far does not show full details.^[16] There is no peer-reviewed paper yet with randomization methods, side effect charts, or long-term kidney outcomes such as changes in filtration rate or cyst volume.^[8]^[13] For now, the strongest human data are on urine volume, thirst, and sleep, not on whether kidneys last longer or dialysis is delayed.

Safety is another brake. The United States Food and Drug Administration label for probenecid warns about uric acid kidney stones, painful urinary blockage, and other kidney-related side effects.^[2]^[10]^[11] The drug also works less well in people with reduced kidney function, which many PKD patients eventually have.^[4]^[5] Probenecid can change how other drugs leave the body, which matters for patients already taking several medicines. Those are not deal-breakers, but they demand careful trials, not wishful thinking.

Repurposed drugs, hard outcomes, and what comes next

Kidney medicine is full of repurposed drugs that started out doing one job and later picked up another. Probenecid now joins bempedoic acid, a cholesterol drug being tested for PKD, and experimental cancer compounds that shrink cysts in mice as part of a crowded pipeline.^[14]^[17]^[21] History shows that many of these hopeful ideas fade when tested against tough endpoints like kidney survival, not just lab numbers.^[18]^[21] That is why serious kidney groups insist on well-designed, placebo-controlled trials before changing practice.

The next steps are clear. Researchers need to publish the full phase 2 data, including how many patients were studied, how they were chosen, and exactly what side effects occurred.^[8]^[13]^[16] Larger trials must test whether probenecid can safely help tolvaptan users over years, not weeks, and whether it adds any true kidney protection beyond better comfort. Until then, the smart stance is cautious optimism. The 1940s gout pill has earned a second look, but not yet a free pass into every PKD medicine cabinet.